Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2003

View Archived Issues

New antidiabetic agents discovered by Indian researchers

Cytokine production inhibitors prepared and tested at Sankyo

Boehringer Ingelheim describes the preparation and use of epoxide hydrolase inhibitors

Novel integrin antagonists and their use reported by Bayer

Takeda scientists prepare CXCR4 antagonists for AIDS and cancer

Recent Bayer patent covers new guanylate cyclase activators

New distribution agreements for Foscan in East Europe and Mediterranean

Long-term inhibition of bone and joint damage in RA patients on Enbrel

NicVAX phase I/II trial begins enrollment

GPC Biotech licenses intellectual property for use with Reverse Genomics platform

DOR BioPharma to license intranasal vaccine technology from U.K.'s Ministry of Defence

Valentis licenses PEGylation technology to Prolong Pharmaceuticals

Axonyx plans to begin two Alzheimer's trials for phenserine in 2003

Clinical trial of Ono insulin sensitizer halted

Licensing opportunity from the NIH: new mouse model for osteoarthritis

NIH offers ligands for FPR receptors that inhibit HIV infection, boost immune response to microbes

AHCD may be reversible after liver transplant; possible role for immunophilin ligands

Members of the quinoline-indole class of antibacterial agents characterized in further detail

AstraZeneca launches Crestor in Canada

Delay announced in European approval for Amevive

Sonic hedgehog protein demonstrates efficacy in diabetic neuropathy

NS-1209 enters phase II for epilepsy

Newly discovered anti-MRSA antibiotic produced by marine bacterium

Acetylcholinesterase inhibitors related to galanthamine claimed by Sankyo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...